3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Dermatologic
1
Conditions
Vomiting
1
Melanoma
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
58
Nivolumab
37
aldesleukin
16
Cyclophosphamide
15
atezolizumab
12
Specimen Handling
11
Radiosurgery
10
Paclitaxel
10
Magnetic Resonance Spectroscopy
10
Ipilimumab
9
Interleukin-2
9
fludarabine
8
fludarabine phosphate
7
Docetaxel
7
Carboplatin
7
avelumab
6
Radiotherapy
6
durvalumab
5
Peripheral Blood Stem Cell Transplantation
5
Immune Checkpoint Inhibitors
5
Cisplatin
5
Bevacizumab
5
tislelizumab
4
temsirolimus
4
spartalizumab
4
Sirolimus
4
Pemetrexed
4
Oxaliplatin
4
Leucovorin
4
Cryosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
fosaprepitant
×
Dermatologic
×
Clear all
NCT01874119
2018-06-07
HDIL2/Emend
St. Louis University
Phase 2
Terminated
13 enrolled
7 charts